CASTLE ROCK, Colo., Nov. 21, 2013 /PRNewswire/-- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its CE Marked APPY1™ Test, a rapid, multiple biomarker-based assay for identifying patients that are at low risk for appendicitis, today announced it will present at the Piper Jaffray 25th Annual Healthcare Conference, to be held December 3-4, 2013, at The New York Palace Hotel in New York, NY.
Steve Lundy, President and CEO of Venaxis™, will provide an overview of the Company's business during his live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference. Event:Piper Jaffray 25th Annual Healthcare ConferenceDate:Tuesday, December 3, 2013 Time:9:30 am (Eastern Time) Location:
The New York Palace Hotel, New York, NY The presentation will be webcast live. To access the webcast, please visit the investor relations section of the Venaxis website at http://ir.venaxis.com. The webcast will be archived and available for 90 days.
Separately, Venaxis is scheduled to ring The NASDAQ Stock Market Closing Bell on December 6, 2013 in a ceremony to celebrate the company's recent achievements as it advances the APPY1 Test toward potential FDA clearance and expands its commercial footprint in the EU. Venaxis remains on track to complete patient enrollment for its pivotal clinical study of the APPY1 Test in the United States at or around the end of 2013.
About Venaxis, Inc.
Venaxis, Inc. is an in vitro diagnostic company focused on the clinical development and commercialization of its CE Marked APPY1 Test, the Company's rapid, protein biomarker-based assay for appendicit
|SOURCE Venaxis, Inc.|
Copyright©2012 PR Newswire.
All rights reserved